Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS

Patients with high-risk features undergoing elective PCI and treated with the more-potent antiplatelet agent ticagrelor (Brilinta; AstraZeneca) instead of clopidogrel fared no better with respect to ... Read More